CANNABINOID DERIVATIVES

1 - 128 . (canceled)

129 . A compound having structural formula:

or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, tautomer, or metabolite, wherein

R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-N(R 1b )—C(O)—O—(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-O—C(O)—NR 1b R 1c , —(C 0 -C 4 alkyl)-N(R 1b )—C(O)—NR 1b R 1c , —OR 1a , —(C 1 -C 4 alkyl)OR 1a , —SR 1a , —(C 1 -C 4 alkyl)S(O) 0-2 R 1a , —NR 1b R 1c , —(C 1 -C 4 alkyl)NR 1b R 1c , —(C 1 -C 4 alkyl)C(O)NR 1b R 1c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl, wherein

R 1a , R 1b , and R 1c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl;

R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —(C 1 -C 4 alkyl)OR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl, wherein

R 2a , R 2b , and R 2c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl;

R 3 is hydrogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 O(C 1 -C 8 alkyl), —(C 0 -C 4 alkyl)-NR 3a R 3b , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl, wherein R 3a and R 3b are each independently hydrogen or C 1 -C 6 alkyl;

R 4 is hydrogen,

 wherein

Q 1 is O or S;

R 4a is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 4c , —(C 1 -C 4 alkyl)OR 4c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 4c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 0-6 (NR 4c R 4d ), —(C 1 -C 4 alkyl)NR 4c R 4d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl,

R 4b is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 4c , —(C 1 -C 4 alkyl)OR 4c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 4c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 0-6 (NR 4c R 4d ), —(C 1 -C 4 alkyl)NR 4c R 4d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl,

wherein R 4c and R 4d are hydrogen or C 1 -C 6 alkyl,

or R 4a and R 4b together with a nitrogen to which they are attached form a heterocycloalkyl or heteroaryl ring, and

R 4e is hydrogen, C 1 -C 8 alkyl, cycloalkyl, or aryl,

R 4f is —OR 4g , C 1 -C 8 alkyl, cycloalkyl, or NR 4h R 4i ,

wherein R 4g is C 1 -C 8 alkyl, cycloalkyl, or aryl, and

wherein R 4h and R 4i are C 1 -C 8 alkyl, or R 4h and R 4i together with a nitrogen to which they are attached form a heterocyloalkyl ring or heteroaryl ring, and

R 4j and R 4k are each independently hydrogen or C 1 -C 8 alkyl;

R 5 is hydrogen, C 1 -C 8 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl);

R 6 is hydrogen or —OR 6a , wherein R 6a is hydrogen, C 1 -C 8 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl); and

R 7 is hydrogen,

 provided that R 7 is not hydrogen when R 4 is hydrogen, wherein Q is O or S;

R 7a is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 7c , —(C 1 -C 4 alkyl)OR 7c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 7c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 0-6 (NR 7c R 7d ), —(C 1 -C 4 alkyl)NR 7c R 7d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl,

R 7b is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 7c , —(C 1 -C 4 alkyl)OR 7c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 7c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 0-6 (NR 7c R 7d ), —(C 1 -C 4 alkyl)NR 7c R 7d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl,

wherein R 7c and R 7d are hydrogen or C 1 -C 6 alkyl,

or R 7a and R 7b together with a nitrogen to which they are attached form a heterocycloalkyl or heteroaryl ring, and

R 7e is hydrogen, C1-C8 alkyl, cycloalkyl, or aryl,

R 7f is —OR 6g , C 1 -C 8 alkyl, cycloalkyl, or NR 7h R 7i ,

wherein R 7g is C 1 -C 8 alkyl, cycloalkyl, or aryl, and

wherein R 7h and R 7i are C 1 -C 8 alkyl, or R 7h and R 7i together with a nitrogen to which they are attached form a heterocyloalkyl ring or heteroaryl ring, and

R 7j and R 7k are each independently hydrogen or C 1 -C 8 alkyl;

wherein

each alkyl, alkenyl and alkynyl is unsubstituted, halogenated, substituted with one or two hydroxyl groups, one or two C 1 -C 6 alkoxy groups, one or two —C(O)O(C 1 -C 4 alkyl) groups, or one or two oxo groups;

each cycloalkyl has 3-10 ring carbons and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each fused ring having 3-8 ring members, and is substituted with 0-6 R 8 ;

each heterocycloalkyl has 3-10 ring members and 1-3 heteroatoms where each is independently nitrogen, oxygen or sulfur and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each having 3-8 ring members, and is substituted with 0-6 R 8 ;

each aryl is a phenyl or a naphthyl, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 9 ;

each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms, where each is independently nitrogen, oxygen or sulfur or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms where each is independently nitrogen, oxygen or sulfur, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 9 ,

in which

each R 8 is independently oxo, C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —(C 0 -C 3 alkyl)-OR B , —NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , —OCO 2 R A , —OC(O)NR B R A , —NR B CO 2 R A , —NR B C(O)NR B R A , —SCO 2 R A , —OC(O)SR A , —SC(O)SR A , —SC(O)NR B R A , —NR B C(O)SR A , —OC(S)OR A , —OC(S)NR B R A , —NR B C(S)OR A , —NR B C(S)NR B R A , —SC(S)OR A , —OC(S)SR A , —SC(S)SR A , —SC(S)NR B R A , —NR B C(S)SR A , —NR B C(NR B )NR B R A , —NR B S(O) 1-2 NR B R A , phenyl, C 3 -C 8 cycloalkyl, a five to six-membered heteroaryl, or a five to six-membered heterocycloalkyl; and

each R 9 is independently optionally-substituted C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —(C 0 -C 3 alkyl)-OR B , —NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —SO 3 H, —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , —OCO 2 R A , —OC(O)NR B R A , —NR B CO 2 R A , —NR B C(O)NR B R A , —SCO 2 R A , —OC(O)SR A , —SC(O)SR A , —SC(O)NR B R A , —NR B C(O)SR A , —OC(S)OR A , —OC(S)NR B R A , —NR B C(S)OR A , —NR B C(S)NR B R A , —SC(S)OR A , —OC(S)SR A , —SC(S)SR A , —SC(S)NR B R A , —NR B C(S)SR A , —NR B C(NR B )NR B R A , —NR B S(O) 1-2 NR B R A , phenyl, C 3 -C 8 cycloalkyl, a five to six-membered heteroaryl, or a five to six-membered heterocycloalkyl;

wherein each R A is independently H or C 1 -C 3 alkyl, and each R B is independently H, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 hydroxyalkyl, —S(O) 1-2 (C 1 -C 3 alkyl), —C(O)(C 1 -C 3 alkyl) or —CO 2 (C 1 -C 3 alkyl).

130 . The compound according to claim 129 , wherein R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-N(R 1b )—C(O)—O—(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-O—C(O)—NR 1b R 1c , —(C 0 -C 4 alkyl)-N(R 1b )—C(O)—NR 1b R 1c , —OR 1a , —(C 1 -C 4 alkyl)OR 1a , —SR 1a , —(C 1 -C 4 alkyl)SR 1a , —NR 1b R 1c , —(C 1 -C 4 alkyl)NR 1b R 1c , —(C 1 -C 4 alkyl)C(O)NR 1b R 1c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl.

131 . The compound according to claim 129 , wherein R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 1 -C 4 alkyl)OR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 -C 4 alkyl)-heterocycloalkyl.

132 . The compound according to claim 129 , wherein R 3 is hydrogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 OCH 3 , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl.

133 . The compound according to claim 129 , wherein R 3 is hydrogen, C 1 -C 12 alkyl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl.

134 . The compound according to claim 129 , wherein R 5 is hydrogen, C 1 -C 6 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), or —C(O)N(C 1 -C 4 alkyl) 2 .

135 . The compound according to claim 129 , wherein R 6 is hydrogen or —OR 6a , wherein R 6a is hydrogen, C 1 -C 6 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), or —C(O)N(C 1 -C 4 alkyl) 2 .

136 . The compound according to claim 129 , wherein the compound is of formula:

137 . The compound according to claim 129 , wherein Q is O.

138 . The compound according to claim 129 , wherein Q is S.

139 . The compound according to claim 129 , wherein each alkyl is unsubstituted.

140 . The compound according to claim 129 , wherein each R 7 is independently oxo, C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , or —NR B S(O) 1-2 R A .

141 . The compound according to claim 129 , which is:

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methoxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-N-ethyl-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-isopropyl-6-pentylbenzamide;

N-acetyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

N-cyclopropyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

N-cyclopentyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-(1-(trifluoromethyl)cyclopentyl)benzamide;

N-cyclohexyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-phenylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-(4-methoxyphenyl)-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-(4-(trifluoromethyl)phenyl)benzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-N-(2,6-dimethylphenyl)-2,4-dihydroxy-6-pentylbenzamide;

N-benzyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-(pyridin-3-ylmethyl)benzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-(pyrimidin-5-ylmethyl)benzamide;

N-(3,4-dimethylisoxazol-5-yl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-(oxazol-5-ylmethyl)-6-pentylbenzamide;

N-((1,3,4-oxadiazol-2-yl)methyl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

N-((1H-tetrazol-5-yl)methyl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

methyl (3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)glycinate;

methyl (3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)-L-alaninate;

methyl (3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)-L-phenylalaninate;

methyl (3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)-L-histidinate;

N-allyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N,N-dimethyl-6-pentylbenzamide;

N-cyclopropyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

N-cyclohexyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentyl-N-phenylbenzamide;

N-benzyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentyl-N-(pyridin-3-ylmethyl)benzamide;

N-((1H-tetrazol-5-yl)methyl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

6-butyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-(isoxazol-3-ylmethyl)-N-methylbenzamide;

(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)methanone;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(4-methylpiperazin-1-yl)methanone;

1-(4-(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)piperazin-1-yl)ethan-1-one;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(4-(methylsulfonyl)piperazin-1-yl)methanone;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(1,1-dioxidothiomorpholino)methanone;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(morpholino)methanone;

methyl (3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)-D-prolinate;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(pyrrolidin-1-yl)methanone;

1-(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzoyl)pyrrolidin-3-one;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(isoindolin-2-yl)methanone;

(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(1H-indol-1-yl)methanone;

aziridin-1-yl(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)methanone;

(S)-(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(2-methylaziridin-1-yl)methanone;

(R)-(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)(2-methylaziridin-1-yl)methanone;

azetidin-1-yl(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)methanone;

(3,3-difluoroazetidin-1-yl)(3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylphenyl)methanone;

3-(3,7-dimethylocta-2,6-dien-1-yl)-N,N-diethyl-2,4-dihydroxy-6-pentylbenzamide;

N-cyano-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methoxy-N-methyl-6-pentylbenzamide;

N-allyl-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-(2-methoxyethyl)-N-methyl-6-pentylbenzamide;

N-(2-(dimethylamino)ethyl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N-methyl-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-N,N-bis(2-hydroxyethyl)-6-pentylbenzamide;

N-(2-bromobenzyl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzamide;

methyl (3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentylbenzyl)(methyl)carbamate;

dimethyl ((5-(3,7-dimethylocta-2,6-dien-1-yl)-4,6-dihydroxy-2-pentyl-1,3-phenylene)bis(methylene))bis(methylcarbamate);

3-(3,7-dimethylocta-2,6-dien-1-yl)-N-(4-fluorophenyl)-2,4-dihydroxy-6-pentyl benzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-N-(4-fluorobenzyl)-2,4-dihydroxy-6-pentylbenzamide;

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-(pyridin-3-ylmethyl)benzamide; or

3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-6-pentyl-N-(pyridin-3-yl) benzamide.

142 . A pharmaceutical composition comprising a compound according to claim 129 , or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, tautomer, or metabolite, together with a pharmaceutically acceptable excipient, diluent, or carrier.

143 . A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 129 or a pharmaceutical composition thereof.

144 . The method according to claim 143 , wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TPRV2, PPARγ or a μ-opioid receptor.

145 . The method according to claim 143 , wherein the cannabinoid receptor is CB1 or CB2.

146 . A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 129 or a pharmaceutical composition thereof, wherein the disease is acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, anxiety disorders, arthritis, atherosclerosis, autism, bipolar disorder, burns, cancer, cancer pain, Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathies, chronic pain, chronic allograft nephropathy, cocaine use disorder, complex regional pain syndrome, congestive heart failure, depression, fibromyalgia, fragile X syndrome/FXTAS, frontotemporal dementias, gingivitis pyrexia, glaucoma, glioblastoma, glomerulonephropathy, Huntington's disease, hypertrophic scars, IBD/IBS, inflammation, Inflammatory myopathies, ischemia, kidney fibrosis, keloids, leukodystrophies, liver fibrosis, liver cirrhosis, lung fibrosis, migraine, multiple sclerosis, myocardial infarction, nausea, neuropathic pain, nightmare disorder, non-alcoholic fatty liver disease, obesity, obsessive-compulsive disorder, opioid sparing, opioid use disorder, osteoarthritis, osteoporosis, Parkinson's, post-concussion syndrome/traumatic brain injury, psychosis/schizophrenia, PTSD, regulation of bone mass, REM sleep behaviour disorder, reperfusion injury, Rett syndrome, rheumatoid arthritis, skin conditions, sleep disorders, spinocerebellar ataxias, systemic fibrosis, systemic sclerosis, thermal injury, tobacco use disorder/nicotine dependence, Tourette's, tumors or trigeminal neuralgia.